The Chocolate Almond Study - Relating Chewing to Satiation and Postprandial Response

NCT ID: NCT07065461

Last Updated: 2025-07-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-01

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to relate chewing behaviours to food intake and postprandial response for a texturally complex food matrix (almonds in white chocolate) in healthy young females. The main questions it aims to answer are:

* Does the presence or preparation of almonds (whole versus chopped) influence satiation, i.e., the amount consumed at an ad libitum meal?
* What is the correlation between chewing behaviour, satiation, and changes in postprandial glucose, triacylglycerols, and satiety ratings? Participants will attend the research centre fasted on three occasions to consume an ad libitum meal, complete questionnaires, and provide fasting and postprandial finger prick blood samples.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is investigating how the size and presence of almonds (whole vs. chopped) in a white chocolate matrix affect satiation (termination of eating) and postprandial satiety, glycemia, and lipemia. Over three visits, fasted healthy adult female participants will consume three types of white chocolate bark: one with whole almonds, one with chopped almonds, and one with just chocolate. The amount of each ad libitum meal consumed and eating time will be quantified to compare satiation between the confectionery products. Participants will rate their chewing experiences (e.g., exertion, liking, motivations to stop eating) and feelings of satiety up to 180 minutes using paper questionnaires. Participants will also provide finger prick blood samples for determination of glucose and triacylglycerol levels before and after eating each treatment, i.e., at baseline (0 minutes) and 120 (glucose) and 180 (triacylglycerols) minutes after eating. Overall, this study aims to provide insights into the role of food structure in influencing eating and metabolic response and ultimately how food choices can be optimized for better management of blood sugar, satiety, and lipemia to support cardiometabolic health. It is being complemented by a collaboration with researchers in the Department of Food Science at the University of Guelph (led by Prof. Lisa Duizer) examining sensory perception of these same texturally complex foods and the relationship between oral processing behaviour and bolus properties, as well as by in vitro digestion investigations of digestate properties and nutrient release to enable an integrated understanding linking food structure to eating behaviour and postprandial metabolism.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Satiation, Satiety Postprandial Glycemia Postprandial Lipemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Acute meal postprandial study
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Investigators Outcome Assessors
Individuals collecting, entering, and analyzing data will be blinded to treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

White chocolate with whole almonds

Ad libitum serving with 2.25:1 weight per cent chocolate:almonds

Group Type EXPERIMENTAL

200 g serving of white chocolate-based confection product

Intervention Type OTHER

200 g serving of white chocolate-based confection product

White chocolate without almonds

Ad libitum serving

Group Type EXPERIMENTAL

200 g serving of white chocolate-based confection product

Intervention Type OTHER

200 g serving of white chocolate-based confection product

White chocolate with chopped almonds

Ad libitum serving with 2.25:1 weight per cent chocolate:almonds

Group Type EXPERIMENTAL

200 g serving of white chocolate-based confection product

Intervention Type OTHER

200 g serving of white chocolate-based confection product

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

200 g serving of white chocolate-based confection product

200 g serving of white chocolate-based confection product

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI between 18.5-27.9 kg/m\^2 or waist circumference less than 88 cm
* No known food allergies or sensitivities
* Non-restrained eaters based on the Three Factor Eating Questionnaire
* No history of gastrointestinal diseases that may interfere with eating behaviour or digestion
* Not on medications that affect appetite, digestion, blood sugar regulation, saliva production, or chewing
* Stable medication use
* Non-smokers
* Not gained or lost significant weight during the past 3 months
* Regular monthly menstrual cycles
* Not pregnant, lactating, or post-menopausal

Exclusion Criteria

* Diabetes or other metabolic disorders affecting glycemia and overall cardiometabolic health
* Any food allergies, intolerance, or sensitivities
* Any life-threatening allergy
* Pregnant or breastfeeding
* Participation in another clinical trial
* Alcohol consumption more than 14 drinks per week
* Smokers or those with a smoking history or more than 10 years
* Regular use of recreational drugs (e.g., marijuana, ecstasy, magic mushrooms)
* Restrained eater as defined by \> 15 on the Three-Factor Eating Questionnaire
* Unusual sleep patterns
* Irregular breakfast consumption
* Recent weight changes or intended weight loss or gain or having lost or gained \>10% of body weight within the last 6 months
* Using medications known to affect appetite, digestion, blood sugar regulation, lipids, or chewing (excluding oral contraceptives)
* Experiences dry mouth, in general or due to medication side effects
* Diagnosed with Sjogren's Syndrome (autoimmune condition linked to severe dry mouth)
* Inability to adhere to study protocols
* Not comfortable providing finger prick blood samples
* Avoids consuming almonds or chocolate
* Has temporomandibular joint disorder (TMJ)
* Has or history or oral cancer
* Recent dental or jaw surgery
* Avoids eating hard foods for concerns of dental fractures or for general oral health
* Individuals with dentures, braces, Invisalign, or other dental implants that cause difficulty chewing
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Guelph

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amanda Wright, Ph.D.

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Human Health Sciences

Guelph, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amanda J Wright, PhD

Role: CONTACT

519-824-4120 ext. 54697

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amanda J Wright, PhD

Role: primary

5190824-4120 ext. 54697

Alison M Duncan, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

400819

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

1669

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.